TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Brexit: Update for the Pharma Industry

Brexit: Update for the Pharma Industry

The mantra over the past two years when it comes to Brexit has been ‘prepare for the worst and hope for the best’. As March 29th closes in, this appears like the best advice possible. Preparations in the Pharmaceutical and Biopharmaceutical industry are in reasonably good shape, and certainly better than other industry sectors, if the mood of last Friday’s HPRA Brexit Stakeholder Meeting on 01 Feb 2019 is reflective of the reality in the industry.

With over 400 participants, 200 of whom signed up within three hours, this was a meeting which captured the industry’s attention. The panel of experts, which consisted of government bodies (Health Products Regulatory Authority, Revenue, Health Service Executive and the Department of Health) and industry representatives (Irish Pharmaceutical Healthcare Association and Medicines for Ireland ) provided short, sharp and clear information on what preparation has been done and what is in progress in relation to a ‘no-deal’ or disorderly Brexit. The participants, who clearly believed by a show of hands that a disorderly Brexit is likely, were highly interested in the latest information from the HPRA on Brexit planning. The advice can be summarised as follows:

  • Know your supply chain and how it ‘touches’ the UK.
  • Be familiar with the regulatory requirements with the UK as third country.
  • Be familiar with the future customs requirements for import and export to the UK.
  • Seek assurances from your suppliers, particularly if UK based.

From a regulatory standpoint, the audience were informed that the EU commission have informally indicated that in cases of non-compliance, Marketing Authorisations (MAs) will not become automatically invalid. The HPRA indicated that quite limited information had been fed back to the HPRA from MA Holder’s. Engagement with the HPRA is strongly advised where risks of non-compliance exist, e.g. where testing and release of medicines will be required from the meeting. The principle reason for this advice is so that the agency can gauge (a) how many products are affected and (b) how regulatory solutions could be prepared and attained.

The key advice for MAH’s who have not yet engaged with the agency was to:

  • Avoid unilateral withdrawals of medicine packs
  • Consider multilingual packs where there are commercial challenges in having a dedicated Irish pack
  • Be aware that Joint UK-Ireland packaging is acceptable after 29 March 2019 (once compliant with Title V of Directive 2004/83/EC and reflects the Summary of Product Characteristics (SMPC) of the product authorised on the Irish market.)

Further specific areas of information from the meeting included:

  • Removal of the requirement for a Manufacturing Importation Authorisation (MIA) when importing exempt (unauthorised) medicines from a third country. There is an amendment to current legislation being progressed and the HPRA have no objection to a Wholesale Distribution Authorisation (WDA) being used for exempt medicine importation from now.
  • An MIA is required for physical importation of authorised medicinal products from a third country, but a WDA is sufficient for financial (or fiscal) importation – which is no change from the existing situation.
  • Wholesalers currently receiving authorised medicinal products from UK distributors must have an MIA in order to act as a site of physical importation after Brexit
  • That where there are clinical trials on-going in Ireland, it was recommended that the Irish entities involved in the trial contact the HPRA for clarification on the sponsor of the trial if they are currently UK based.
  • For medicinal products ‘mid-application’ where the UK is the Reference Member State (RMS), there is a consultation happening with MHRA for critical medicines to determine whether the HPRA or other EU National Competent Authorities (NCAs) would take on the application for assessment.
  • There will be a commission led expert technical seminar for EU27 NCAs on February 18, 2019 to review the ‘no-deal’ Brexit scenario. HPRA are preparing for the potential to issue more detailed guidance in the event of a ‘no-deal Brexit’.

Brexit planning in the pharma sector appears well developed but there are no absolutes in terms of preparation for the unknown. ‘Preparing for the worst and hoping for the best’ will continue until further notice!

We, at PharmaLex, can support your organisation in many ways including the provision of regulatory support for MAH’s, performance of Brexit readiness assessments or provision of a collaborative responses to any technical queries that you may have in relation to Brexit.  Please connect with us to discuss +353 1 846 4742 or email us at contactirl@pharmalex.com.

Related posts
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
5h

At PharmaLex, one of our core values is expanding our global community. In March, we welcomed Japan, East Asia, and Southeast Asia into our global pharmaceutical #productdevelopment as a result of a merger agreement with Ascent Development Services.
https://lnkd.in/eGFf_AKv

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Worked with us and our contractors to help us achieve our tight targets, operate with our systems and procedures and are considered invaluable part of our team

    US based large development group
    VP Regulatory / Quality
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for